KPC Pharmaceuticals,Inc. (SHA:600422)

Market Cap	10.57B
Revenue (ttm)	7.96B
Net Income (ttm)	575.17M
Shares Out	756.98M
EPS (ttm)	0.76
PE Ratio	18.40
Forward PE	15.46
Dividend	0.30 (2.15%)
Ex-Dividend Date	Jul 30, 2025

Volume	1,016,734
Average Volume	9,483,394
Open	13.86
Previous Close	14.03
Day's Range	13.85 - 14.00
52-Week Range	13.48 - 18.64
Beta	0.00
RSI	39.27
Earnings Date	Oct 24, 2025

About KPC Pharmaceuticals,Inc.

KPC Pharmaceuticals,Inc., a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People’s Republic of China and internationally. It offers artemisia annua series, panax notoginseng, gastrodia, specialty herbal, fine Chinese, and classic prescription for bones and joint, antibiotic, immunosuppressive, and others. The company provides medicine and food, skin care, oral care, private care, and time-honored food series; and other products, such as oral medication ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1951
• Employees: 5,275
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600422

Financial Performance

In 2024, KPC Pharmaceuticals,Inc.'s revenue was 8.40 billion, a decrease of -0.34% compared to the previous year's 8.43 billion. Earnings were 648.08 million, an increase of 19.86%.